NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun BioTech June 29, 2023 NanoViricides, Inc. (NYSE American:NNVC) (the Company) reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17,…
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 BioTech September 16, 2020 NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) a global leader in the development of highly effective antiviral therapies based on a…
